GSK3B and neoplasm: Additionally, the PI3K inhibitor, LY294002, significantly inhibited the phosphorylation of AKT and GSK-3β which consequently decreased the nuclear localization of β-catenin and therefore suppressed the tumor-promoting effects of PA.